Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Fanny Le Du"'
Autor:
Julien Corné, Véronique Quillien, Florence Godey, Mathilde Cherel, Agathe Cochet, Fanny Le Du, Lucie Robert, Héloïse Bourien, Angélique Brunot, Laurence Crouzet, Christophe Perrin, Claudia Lefeuvre‐Plesse, Véronique Diéras, Thibault De la Motte Rouge
Publikováno v:
Molecular Oncology, Vol 18, Iss 11, Pp 2714-2729 (2024)
Erb‐b2 receptor tyrosine kinase 2 (ERBB2)‐activating mutations are therapeutically actionable alterations found in various cancers, including metastatic breast cancer (MBC). We developed multiplex digital PCR assays to detect and quantify ERBB2 m
Externí odkaz:
https://doaj.org/article/d0a0f127e91c4930a10cc399be686cfa
Autor:
Charlotte Bellier, Laurence Gladieff, Fanny Le Du, Dominique Berton, Charlotte Bonnard, Delphine Suau, Anne-Céline Richard, Ophélie Brenner, Amir Lahouegue, Gilles Freyer, Anne Floquet, Sophie Frank, Maria Kfoury
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 2, Pp 207-213 (2023)
Abstract Background Olaparib, a poly(ADP-ribose) polymerase inhibitor, was approved by the European Commission in June 2019, following the results of the SOLO-1/GOG 3004 trial as maintenance monotherapy in adult patients with BRCA-mutated epithelial
Externí odkaz:
https://doaj.org/article/3c9b9e59c93c484eb7c9c1cf8bc5d447
Autor:
Julien Corné, Fanny Le Du, Véronique Quillien, Florence Godey, Lucie Robert, Héloïse Bourien, Angélique Brunot, Laurence Crouzet, Christophe Perrin, Claudia Lefeuvre-Plesse, Véronique Diéras, Thibault De la Motte Rouge
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract With the approval of new therapies targeting the PI3K pathway, the detection of PIK3CA mutations has become a key factor in treatment management for HR+/HER2− metastatic breast cancer (MBC). We developed multiplex digital PCR (dPCR) assays
Externí odkaz:
https://doaj.org/article/493c25d955e1403bb36fc1a721cea902
Autor:
Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, Kaldoun Kerrou, Jean-Marc Ferrero, Thierry Petit, Fanny Le Du, Pierre-François Dupré, Thomas Bachelot, Philippe Gabelle, Marie-Pierre Chauvet, David Coeffic, Catherine Barbe, Jean-Briac Prevost, Gilles Paintaud, Gilles Thibault, Abdennour Ferhat, Julien Dupin, Alina Berriolo-Riedinger, Laurent Arnould
Publikováno v:
EClinicalMedicine, Vol 28, Iss , Pp 100566- (2020)
Background: The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bev
Externí odkaz:
https://doaj.org/article/e12828e210e34b18a595bb3ec526544b
Autor:
Fanny Le Du, Takeo Fujii, Kumiko Kida, Darren W Davis, Minjeong Park, Diane D Liu, Weiguo Wu, Mariana Chavez-MacGregor, Carlos H Barcenas, Vicente Valero, Debu Tripathy, James M Reuben, Naoto T Ueno
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229903 (2020)
BackgroundTumor cells with a mesenchymal phenotype and/or cancer stem-like cells (CSCs) are known to contribute to metastasis and drug resistance. Circulating tumor cells (CTCs) undergoing epithelial-mesenchymal transition (EMT) and CTCs reflecting a
Externí odkaz:
https://doaj.org/article/ed1d5dea18d847e38b50809efaf6b772
Autor:
Celine Lefebvre, Thomas Bachelot, Thomas Filleron, Marion Pedrero, Mario Campone, Jean-Charles Soria, Christophe Massard, Christelle Lévy, Monica Arnedos, Magali Lacroix-Triki, Julie Garrabey, Yannick Boursin, Marc Deloger, Yu Fu, Frédéric Commo, Véronique Scott, Ludovic Lacroix, Maria Vittoria Dieci, Maud Kamal, Véronique Diéras, Anthony Gonçalves, Jean-Marc Ferrerro, Gilles Romieu, Laurence Vanlemmens, Marie-Ange Mouret Reynier, Jean-Christophe Théry, Fanny Le Du, Séverine Guiu, Florence Dalenc, Gilles Clapisson, Hervé Bonnefoi, Marta Jimenez, Christophe Le Tourneau, Fabrice André
Publikováno v:
PLoS Medicine, Vol 13, Iss 12, p e1002201 (2016)
BackgroundMajor advances have been achieved in the characterization of early breast cancer (eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes, yet limited information is available on the genomic profile of this di
Externí odkaz:
https://doaj.org/article/4906ba3a0f8142e6be54f521f2af267f
Autor:
Antoine Deleuze, Christophe Massard, Fanny Le Du, Benoit You, Claudia Lefeuvre-Plesse, Pierre-Adrien Bolze, Thibault de la Motte Rouge
Publikováno v:
Expert Review of Anticancer Therapy. :1-10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aaf1d64d2f93a595ef11c9421501c589
https://doi.org/10.1080/14737140.2023.2215438
https://doi.org/10.1080/14737140.2023.2215438
Autor:
Fanny Le Du, Matthieu Carton, Mahasti Saghatchian, David Perol, Barbara Pistilli, Etienne Brain, Delphine Loirat, Laurence Vanlemmens, Thomas Vermeulin, Christelle Levy, Anthony Goncalves, Mony Ung, Marie Robert, Anne Jaffre, Mathieu Robain, Suzette Delaloge, Véronique Dieras
Publikováno v:
Cancer Research. 82:P1-18
Background: The management of HER2+ BC has changed dramatically with the introduction and widespread use of HER2-targeted therapies, especially in the adjuvant setting. It is well-known that de novo metastatic HER2+ breast cancer patients have better
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91dd7f0ad424518a77b8b8178ded54ab
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-09
https://doi.org/10.1158/1538-7445.sabcs21-p1-18-09
Refining Therapy in Patients with HER2-Positive Breast Cancer with Central Nervous System Metastasis
Autor:
Marta Filipa Freire Vaz Batista, Inês Eiriz, Amanda Fitzpatrick, Fanny Le Du, Sofia Braga, Diogo Alpuim Costa
Publikováno v:
Breast Care. 17:524-532
Background: Brain metastasis (BM) is a major clinical problem in metastatic breast cancer (MBC), occurring in 50% of patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Historically omitted from clinical trials, rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60f7b064726eb8671cd27bd1bfe5034e
https://doi.org/10.1159/000526431
https://doi.org/10.1159/000526431
Autor:
Prudence A, Francis, Gini F, Fleming, István, Láng, Eva M, Ciruelos, Hervé R, Bonnefoi, Meritxell, Bellet, Antonio, Bernardo, Miguel A, Climent, Silvana, Martino, Begoña, Bermejo, Harold J, Burstein, Nancy E, Davidson, Charles E, Geyer, Barbara A, Walley, James N, Ingle, Robert E, Coleman, Bettina, Müller, Fanny, Le Du, Sibylle, Loibl, Eric P, Winer, Barbara, Ruepp, Sherene, Loi, Marco, Colleoni, Alan S, Coates, Richard D, Gelber, Aron, Goldhirsch, Meredith M, Regan
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5424a95a06977301869a1612e2b4b1b
https://pubmed.ncbi.nlm.nih.gov/36493334
https://pubmed.ncbi.nlm.nih.gov/36493334